When GLP-1 Agonists Shut Down Your Gut for Weeks

What They Found

A patient with bulimia nervosa developed prolonged paralytic ileus—complete cessation of bowel motility—following an intentional tirzepatide overdose. The gastroparesis persisted for weeks, requiring intensive medical management to restore normal gastrointestinal function.

Why It Matters

This case exposes the darker side of GLP-1/GIP dual agonism that most weight loss discussions ignore. Tirzepatide works partly by dramatically slowing gastric emptying—usually a beneficial effect for satiety and glycemic control. But this mechanism has a dose-dependent ceiling where therapeutic becomes pathologic.

The patient's underlying bulimia nervosa likely compounded the risk. Eating disorders already disrupt normal gastric motility patterns, and the combination of purging behaviors with a high-dose GLP-1 receptor agonist created a perfect storm for complete gastrointestinal shutdown. The prolonged nature of this paralytic ileus suggests that tirzepatide's effects on enteric nervous system function may persist well beyond plasma half-life at supratherapeutic doses.

This isn't theoretical risk management—it's a real clinical scenario that could present to any emergency department. The case demonstrates how the same incretin pathways that provide metabolic benefits can become dangerous when dysregulated, particularly in vulnerable patient populations.

What I'd Watch For

This single case report can't establish causation or predict frequency, but it raises critical questions about screening protocols. Are we adequately assessing eating disorder history before prescribing GLP-1 agonists? The gastroparesis risk isn't limited to overdose scenarios—even therapeutic doses can cause significant gastrointestinal complications in predisposed individuals.

We need systematic studies examining GI motility outcomes across different patient populations, particularly those with psychiatric comorbidities or prior gastrointestinal dysfunction. Current prescribing guidelines may be insufficient for identifying high-risk patients.

Bottom Line

This case should make any clinician pause before prescribing tirzepatide to patients with eating disorder histories. The risk-benefit calculation changes dramatically when therapeutic mechanisms can trigger weeks of paralytic ileus. Screen harder, start lower, and monitor GI symptoms more closely than current protocols suggest.